Cargando…
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, mo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564553/ https://www.ncbi.nlm.nih.gov/pubmed/32937961 http://dx.doi.org/10.3390/jcm9092967 |
_version_ | 1783595740879126528 |
---|---|
author | Macpherson, Anne M. Barry, Simon C. Ricciardelli, Carmela Oehler, Martin K. |
author_facet | Macpherson, Anne M. Barry, Simon C. Ricciardelli, Carmela Oehler, Martin K. |
author_sort | Macpherson, Anne M. |
collection | PubMed |
description | Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer. |
format | Online Article Text |
id | pubmed-7564553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75645532020-10-29 Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy Macpherson, Anne M. Barry, Simon C. Ricciardelli, Carmela Oehler, Martin K. J Clin Med Review Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer. MDPI 2020-09-14 /pmc/articles/PMC7564553/ /pubmed/32937961 http://dx.doi.org/10.3390/jcm9092967 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Macpherson, Anne M. Barry, Simon C. Ricciardelli, Carmela Oehler, Martin K. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title_full | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title_fullStr | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title_full_unstemmed | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title_short | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
title_sort | epithelial ovarian cancer and the immune system: biology, interactions, challenges and potential advances for immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564553/ https://www.ncbi.nlm.nih.gov/pubmed/32937961 http://dx.doi.org/10.3390/jcm9092967 |
work_keys_str_mv | AT macphersonannem epithelialovariancancerandtheimmunesystembiologyinteractionschallengesandpotentialadvancesforimmunotherapy AT barrysimonc epithelialovariancancerandtheimmunesystembiologyinteractionschallengesandpotentialadvancesforimmunotherapy AT ricciardellicarmela epithelialovariancancerandtheimmunesystembiologyinteractionschallengesandpotentialadvancesforimmunotherapy AT oehlermartink epithelialovariancancerandtheimmunesystembiologyinteractionschallengesandpotentialadvancesforimmunotherapy |